MedTrace Logo

Rasagiline as Add on to Dopamine Agonists in the Treatment of Parkinson's Disease

NCT01049984 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 328

Last updated 2016-05-20

Study results available
· View outcomes & findings →

Summary

To assess the efficacy of rasagiline 1 mg as a first add-on treatment to dopamine agonist therapy in early Parkinson Disease (PD) patients, , not optimally controlled on dopamine agonists as compared to placebo.

Conditions

Interventions

DRUG

Rasagiline

1mg tablet daily for 18 weeks

DRUG

Placebo

one tablet daily for 18 weeks

Sponsors & Collaborators

  • H. Lundbeck A/S

    collaborator INDUSTRY

  • Teva Neuroscience, Inc.

    lead INDUSTRY

Principal Investigators

  • Azhar Choudhry, M.D. · Teva Neuroscience, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2012-10-31
Completion
2012-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01049984 on ClinicalTrials.gov